22 results on '"Gu, V"'
Search Results
2. 689P DB-1305 (a Trop-2 targeted antibody-drug-conjugate [ADC]) in patients (pts) with advanced solid tumors: Preliminary clinical results from the phase (Ph) I/IIa study
- Author
-
Marathe, O., Cheng, Y., Spira, A.I., Hamilton, E.P., Rubinstein, M.M., Dong, X., Li, L., Lv, D., Shi, J., Gabrail, N., Amin, H., Wu, C., Zhu, Z., Qiu, Y., Gu, V., Qiu, X., Shi, R., Liu, L., Miao, P., and Ueno, N.T.
- Published
- 2023
- Full Text
- View/download PDF
3. The Biomolecular Interaction Network Database and related tools 2005 update
- Author
-
Alfarano, C., Andrade, C. E., Anthony, K., Bahroos, N., Bajec, M., Bantoft, K., Betel, D., Bobechko, B., Boutilier, K., Burgess, E., Buzadzija, K., Cavero, R., D'Abreo, C., Donaldson, I., Dorairajoo, D., Dumontier, M. J., Dumontier, M. R., Earles, V., Farrall, R., Feldman, H., Garderman, E., Gong, Y., Gonzaga, R., Grytsan, V., Gryz, E., Gu, V., Haldorsen, E., Halupa, A., Haw, R., Hrvojic, A., Hurrell, L., Isserlin, R., Jack, F., Juma, F., Khan, A., Kon, T., Konopinsky, S., Le, V., Lee, E., Ling, S., Magidin, M., Moniakis, J., Montojo, J., Moore, S., Muskat, B., Ng, I., Paraiso, J. P., Parker, B., Pintilie, G., Pirone, R., Salama, J. J., Sgro, S., Shan, T., Shu, Y., Siew, J., Skinner, D., Snyder, K., Stasiuk, R., Strumpf, D., Tuekam, B., Tao, S., Wang, Z., White, M., Willis, R., Wolting, C., Wong, S., Wrong, A., Xin, C., Yao, R., Yates, B., Zhang, S., Zheng, K., Pawson, T., Ouellette, B. F. F., and Hogue, C. W. V.
- Published
- 2005
4. Aspirin and Extended-Release Dipyridamole versus Clopidogrel for Recurrent Stroke
- Author
-
Sacco, Rl, Diener, Hc, Yusuf, S, Cotton, D, Ounpuu, S, Lawton, Wa, Palesch, Y, Martin, Rh, Albers, Gw, Bath, P, Bornstein, N, Chan, Bp, Chen, St, Cunha, L, Dahlöf, B, DE KEYSER, J, Donnan, Ga, Estol, C, Gorelick, P, Gu, V, Hermansson, K, Hilbrich, L, Kaste, M, Lu, C, Machnig, T, Pais, P, Roberts, R, Skvortsova, V, Teal, P, Toni, Danilo, Vandermaelen, C, Voigt, T, Weber, M, Yoon, Bw, Lembo, Giuseppe, Rasura, Maurizia, Sacchetti, Maria Luisa, Faculteit Medische Wetenschappen/UMCG, Gerontology, Department of neurology, University of Miami Leonard M. Miller School of Medicine (UMMSM)-University of Miami [Coral Gables], Universität Duisburg-Essen [Essen], Boehringer Ingelheim GmbH, Boehringer Ingelheim Pharmaceuticals, Population Health Research Institute, McMaster University [Hamilton, Ontario]-Hamilton General Hospital, Boehringer Ingelheim, Boehringer Ingelheim Ltd, Department of biostatistics, Bioinformatics and Epidemiology, Medical University of South Carolina [Charleston] (MUSC), Neurology and Neurological Sciences, Stanford University, Stroke Trials Unit, University of Nottingham, UK (UON), Neurology Department, Ichilov Medical Center, Division of Neurology, Department of Medicine, National University Hospital Singapore, Department of Neurology, Chang Gung Memorial Hospital [Taipei] (CGMH), Neurology department, Universidade de Coimbra [Coimbra], Institute of Medicine, Sahlgrenska University Hospital [Gothenburg], University Medical Center Groningen [Groningen] (UMCG), National Stroke Research Institute, University of Melbourne, Neurological Center for Treatment and Research, Department of Neurology and Rehabilitation, University of Illinois System, Boehringer Ingelheim Shanghai Pharmaceuticals Co Ltd, Boehringer Ingelheim AB, Helsinki University Central Hospital, Huashan Hospital [Shangai], Saint John's Medical College, Clinical Trials Methodoloy Group, McMaster University [Hamilton, Ontario], Neurology & Neurosurgery Clinic, Russian State Medical University, Department of Medicine, Neurology, Faculty of Medicine, University of British Columbia (UBC), Department of Neurological Sciences, Università degli Studi di Roma 'La Sapienza' = Sapienza University [Rome], Cardiology Department, SUNY Downstate Medical Center, State University of New York (SUNY)-State University of New York (SUNY), Seoul National University Hospital, Service de Neurologie [CHU Limoges], CHU Limoges, Neuroépidémiologie Tropicale et Comparée (NETEC), Génomique, Environnement, Immunité, Santé, Thérapeutique (GEIST FR CNRS 3503)-Institut d'Epidémiologie Neurologique et de Neurologie Tropicale-Université de Limoges (UNILIM), Université de Limoges (UNILIM)-Institut d'Epidémiologie Neurologique et de Neurologie Tropicale-Génomique, Environnement, Immunité, Santé, Thérapeutique (GEIST FR CNRS 3503), Sacco, Rl, Diener, Hc, Yusuf, S, Cotton, D, Ounpuu, S, Lawton, Wa, Palesch, Y, Martin, Rh, Albers, Gw, Bath, P, Bornstein, N, Chan, Bp, Chen, St, Cunha, L, Dahlof, B, DE KEYSER, J, Donnan, Ga, Estol, C, Gorelick, P, Gu, V, Hermansson, K, Hilbrich, L, Kaste, M, Lu, C, Machnig, T, Pais, P, Roberts, R, Skvortsova, V, Teal, P, Toni, D, Vandermaelen, C, Voigt, T, Weberm, Yoon, Bw, and Comi, Giancarlo
- Subjects
Male ,Myocardial Infarction ,Angiotensin-Converting Enzyme Inhibitors ,MESH: Cognition ,Brain Ischemia ,NON-INFERIORITY TRIALS ,0302 clinical medicine ,aspirina ,Secondary Prevention ,Aspirin ,MESH: Middle Aged ,MESH: Risk ,Hazard ratio ,MESH: Disability Evaluation ,MESH: Brain Ischemia ,Dipyridamole ,MESH: Follow-Up Studies ,ARTERIAL ORIGIN ESPRIT ,General Medicine ,RANDOMIZED CONTROLLED-TRIAL ,3. Good health ,MESH: Myocardial Infarction ,Platelet aggregation inhibitor ,Drug Therapy, Combination ,MESH: Hemorrhage ,medicine.medical_specialty ,MESH: Ticlopidine ,MESH: Delayed-Action Preparations ,MESH: Drug Delivery Systems ,MESH: Factor Analysis, Statistical ,Hemorrhage ,MESH: Drug Administration Schedule ,MESH: Stroke ,03 medical and health sciences ,MESH: Severity of Illness Index ,Humans ,Vascular Diseases ,ACTIVE CONTROLLED-TRIALS ,MESH: Kaplan-Meier Estimate ,Aged ,ictus ,trial clinico ,MESH: Humans ,Proportional hazards model ,MESH: Angiotensin II Type 1 Receptor Blockers ,MESH: Retrospective Studies ,medicine.disease ,MESH: Benzoates ,PREVENTION ,MESH: International Cooperation ,Delayed-Action Preparations ,Benzimidazoles ,Factor Analysis, Statistical ,MESH: Mental Status Schedule ,MESH: Female ,030217 neurology & neurosurgery ,Kaplan-Meier Estimate ,030204 cardiovascular system & hematology ,Benzoates ,MESH: Proportional Hazards Models ,DOUBLE-BLIND ,MESH: Double-Blind Method ,Telmisartan ,Stroke ,MESH: Aged ,MESH: Angiotensin-Converting Enzyme Inhibitors ,Middle Aged ,Clopidogrel ,MESH: Platelet Aggregation Inhibitors ,Anesthesia ,MESH: Vascular Diseases ,Cardiology ,Female ,[SDV.NEU]Life Sciences [q-bio]/Neurons and Cognition [q-bio.NC] ,medicine.drug ,Risk ,Double-Blind Method ,TICLOPIDINE ,Internal medicine ,medicine ,cardiovascular diseases ,MESH: Aspirin ,Ticlopidine ,HIGH-RISK PATIENTS ,Proportional Hazards Models ,CEREBRAL-ISCHEMIA ,business.industry ,MESH: Male ,MESH: Recurrence ,MESH: Drug Therapy, Combination ,TRANSIENT ISCHEMIC ATTACK ,MESH: Dipyridamole ,[SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologie ,MESH: Benzimidazoles ,business ,Platelet Aggregation Inhibitors - Abstract
Prevention Regimen for Effectively Avoiding Second Strokes (PRoFESS) trial; International audience; BACKGROUND: Recurrent stroke is a frequent, disabling event after ischemic stroke. This study compared the efficacy and safety of two antiplatelet regimens--aspirin plus extended-release dipyridamole (ASA-ERDP) versus clopidogrel. METHODS: In this double-blind, 2-by-2 factorial trial, we randomly assigned patients to receive 25 mg of aspirin plus 200 mg of extended-release dipyridamole twice daily or to receive 75 mg of clopidogrel daily. The primary outcome was first recurrence of stroke. The secondary outcome was a composite of stroke, myocardial infarction, or death from vascular causes. Sequential statistical testing of noninferiority (margin of 1.075), followed by superiority testing, was planned. RESULTS: A total of 20,332 patients were followed for a mean of 2.5 years. Recurrent stroke occurred in 916 patients (9.0%) receiving ASA-ERDP and in 898 patients (8.8%) receiving clopidogrel (hazard ratio, 1.01; 95% confidence interval [CI], 0.92 to 1.11). The secondary outcome occurred in 1333 patients (13.1%) in each group (hazard ratio for ASA-ERDP, 0.99; 95% CI, 0.92 to 1.07). There were more major hemorrhagic events among ASA-ERDP recipients (419 [4.1%]) than among clopidogrel recipients (365 [3.6%]) (hazard ratio, 1.15; 95% CI, 1.00 to 1.32), including intracranial hemorrhage (hazard ratio, 1.42; 95% CI, 1.11 to 1.83). The net risk of recurrent stroke or major hemorrhagic event was similar in the two groups (1194 ASA-ERDP recipients [11.7%], vs. 1156 clopidogrel recipients [11.4%]; hazard ratio, 1.03; 95% CI, 0.95 to 1.11). CONCLUSIONS: The trial did not meet the predefined criteria for noninferiority but showed similar rates of recurrent stroke with ASA-ERDP and with clopidogrel. There is no evidence that either of the two treatments was superior to the other in the prevention of recurrent stroke. (ClinicalTrials.gov number, NCT00153062.)
- Published
- 2008
- Full Text
- View/download PDF
5. Telmisartan to prevent recurrent stroke and cardiovascular events
- Author
-
Yusuf, S, Diener, Hc, Sacco, Rl, Cotton, D, Ounpuu, S, Lawton, Wa, Palesch, Y, Martin, Rh, Albers, Gw, Bath, P, Bornstein, N, Chan, Bp, Chen, St, Cunha, L, Dahlöf, B, DE KEYSER, J, Donnan, Ga, Estol, C, Gorelick, P, Gu, V, Hermansson, K, Hilbrich, L, Kaste, M, Lu, C, Machnig, T, Pais, P, Roberts, R, Skvortsova, V, Teal, P, Toni, Danilo, Vandermaelen, C, Voigt, T, Weber, M, Yoon, Bw, Lembo, Giuseppe, Rasura, Maurizia, Sacchetti, Maria Luisa, Hamilton General Hospital, Population Health Research Institute, McMaster University [Hamilton, Ontario]-Hamilton General Hospital, Universität Duisburg-Essen [Essen], Miller School of Medicine, University of Miami [Coral Gables], Institute of Medicine, Sahlgrenska University Hospital, Helsinki University, Institut de Génétique Moléculaire de Montpellier ( IGMM ), Université de Montpellier ( UM ) -Centre National de la Recherche Scientifique ( CNRS ), Neuroépidémiologie Tropicale et Comparée ( NETEC ), Génomique, Environnement, Immunité, Santé, Thérapeutique ( GEIST FR CNRS 3503 ) -Institut d'Epidémiologie Neurologique et de Neurologie Tropicale-Université de Limoges ( UNILIM ), Service de Neurologie [CHU Limoges], CHU Limoges, University of Miami Leonard M. Miller School of Medicine (UMMSM), Sahlgrenska University Hospital [Gothenburg], University of Helsinki, Institut de Génétique Moléculaire de Montpellier (IGMM), Centre National de la Recherche Scientifique (CNRS)-Université de Montpellier (UM), Yusuf, S, Diener, Hc, Sacco, Rl, Cotton, D, Ounpuu, S, Lawton, Wa, Palesch, Y, Martin, Rh, Albers, Gw, Bath, P, Bornstein, N, Chan, Bp, Chen, St, Cunha, L, Dahlof, B, De Keyser, J, Donnan, Ga, Estol, C, Gorelick, P, Gu, V, Hermansson, K, Hilbrich, L, Kaste, M, Lu, C, Machnig, T, Pais, P, Roberts, R, Skvortsova, V, Teal, P, Toni, D, Vandermaelen, C, Voigt, T, Weber, M, Yoon, Bw, Comi, Giancarlo, PRoFESS Stuy, Group, Gerontology, and Faculteit Medische Wetenschappen/UMCG
- Subjects
Male ,MESH: Treatment Failure ,MESH : Recurrence ,Myocardial Infarction ,MESH : Aged ,Angiotensin-Converting Enzyme Inhibitors ,Blood Pressure ,BLOOD-PRESSURE ,0302 clinical medicine ,DESIGN ,Secondary Prevention ,MESH : Cardiovascular Diseases ,Myocardial infarction ,MESH: Middle Aged ,Hazard ratio ,General Medicine ,MESH: Follow-Up Studies ,MESH: Blood Pressure ,3. Good health ,MESH: Myocardial Infarction ,MESH : Diabetes Mellitus ,Cardiovascular Diseases ,Creatinine ,MESH : Angiotensin-Converting Enzyme Inhibitors ,Ramipril ,medicine.medical_specialty ,MESH: Diabetes Mellitus ,MESH: Creatinine ,[ SDV.MHEP.GEG ] Life Sciences [q-bio]/Human health and pathology/Geriatry and gerontology ,Article ,MESH: Stroke ,03 medical and health sciences ,MESH : Treatment Failure ,[SDV.MHEP.CSC]Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular system ,Diabetes Mellitus ,Humans ,MESH : Middle Aged ,COMBINATION ,MESH: Kaplan-Meier Estimate ,Aged ,Heart Failure ,MESH: Humans ,VASCULAR EVENTS ,MORTALITY ,MESH : Humans ,MESH : Creatinine ,MESH: Cardiovascular Diseases ,MESH : Follow-Up Studies ,medicine.disease ,MESH: Benzoates ,RAMIPRIL ,Blood pressure ,MESH : Potassium ,Potassium ,Benzimidazoles ,MESH : Heart Failure ,MESH: Female ,030217 neurology & neurosurgery ,MESH : Stroke ,RATIONALE ,Kaplan-Meier Estimate ,030204 cardiovascular system & hematology ,Benzoates ,RANDOMIZED TRIAL ,DOUBLE-BLIND ,MESH : Female ,sartani ,ictus ,trial clinico ,Telmisartan ,Treatment Failure ,Stroke ,MESH: Aged ,[SDV.MHEP.GEG]Life Sciences [q-bio]/Human health and pathology/Geriatry and gerontology ,MESH: Angiotensin-Converting Enzyme Inhibitors ,Middle Aged ,[ SDV.MHEP.CSC ] Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular system ,MESH : Benzimidazoles ,Cardiology ,Female ,medicine.drug ,MESH : Benzoates ,MESH : Male ,MESH : Kaplan-Meier Estimate ,Internal medicine ,Diabetes mellitus ,medicine ,MESH : Blood Pressure ,HIGH-RISK PATIENTS ,business.industry ,Angiotensin II ,MESH: Male ,Surgery ,MESH: Recurrence ,MESH: Heart Failure ,MESH: Potassium ,MESH : Myocardial Infarction ,business ,MESH: Benzimidazoles ,Follow-Up Studies - Abstract
Background: Prolonged lowering of blood pressure after a stroke reduces the risk of recurrent stroke. In addition, inhibition of the renin-angiotensin system in high-risk patients reduces the rate of subsequent cardiovascular events, including stroke. However, the effect of lowering of blood pressure with a renin-angiotensin system inhibitor soon after a stroke has not been clearly established. We evaluated the effects of therapy with an angiotensin-receptor blocker, telmisartan, initiated early after a stroke.Methods: In a multicenter trial involving 20,332 patients who recently had an ischemic stroke, we randomly assigned 10,146 to receive telmisartan (80 mg daily) and 10,186 to receive placebo. The primary outcome was recurrent stroke. Secondary outcomes were major cardiovascular events (death from cardiovascular causes, recurrent stroke, myocardial infarction, or new or worsening heart failure) and new-onset diabetes.Results: The median interval from stroke to randomization was 15 days. During a mean follow-up of 2.5 years, the mean blood pressure was 3.8/2.0 mm Hg lower in the telmisartan group than in the placebo group. A total of 880 patients (8.7%) in the telmisartan group and 934 patients (9.2%) in the placebo group had a subsequent stroke (hazard ratio in the telmisartan group, 0.95; 95% confidence interval [CI], 0.86 to 1.04; P=0.23). Major cardiovascular events occurred in 1367 patients (13.5%) in the telmisartan group and 1463 patients (14.4%) in the placebo group (hazard ratio, 0.94; 95% CI, 0.87 to 1.01; P=0.11). New-onset diabetes occurred in 1.7% of the telmisartan group and 2.1% of the placebo group (hazard ratio, 0.82; 95% CI, 0.65 to 1.04; P=0.10).Conclusions: Therapy with telmisartan initiated soon after an ischemic stroke and continued for 2.5 years did not significantly lower the rate of recurrent stroke, major cardiovascular events, or diabetes. (ClinicalTrials.gov number, NCT00153062.).
- Published
- 2008
- Full Text
- View/download PDF
6. Prevention Regimen for effectively avoiding second strokes (PRoFESS) study group
- Author
-
DIENER HC, SACCO RL, YUSUF S, COTTON D, OUNPUU S, LAWTON WA, PALESCH Y, MARTIN RH, ALEBRS GW, BATH P, BORNSTEIN N, CHAN BP, CHEN ST, CUNHA L, DAHLOF B, DE KEYSER J, DONNAN GA, ESTOL C, GORELICK P, GU V, TEAL P, TONI D, VANDER MAELEN C, VOIGT T, WEBER M, COMI , GIANCARLO, Diener, Hc, Sacco, Rl, Yusuf, S, Cotton, D, Ounpuu, S, Lawton, Wa, Palesch, Y, Martin, Rh, Alebrs, Gw, Bath, P, Bornstein, N, Chan, Bp, Chen, St, Cunha, L, Dahlof, B, DE KEYSER, J, Donnan, Ga, Estol, C, Gorelick, P, Gu, V, Teal, P, Toni, D, VANDER MAELEN, C, Voigt, T, Weber, M, and Comi, Giancarlo
- Published
- 2008
7. effects of apsirin plus extended-release dipyridamole versus clopidogrel and telmisartan on disability and cognitive function after recurrent stroke in patients with ischaemic stroke in the Prevention regimen for Effectively Avoiding Second Strokes (Profess) trial: a double-bind, active and placebo controled study
- Author
-
YUSUF, S, DIENER HC, SACCO RL, COTTON D, OUNPUU S, LAWTON WA PALESCH Y. MARTIN RH ALBERS GW, BATH P, BORNSTEIN N, CHAN BP, CHEN ST, CUNHA L, DAHLOF B, DE KEYSER J, DONNAN GA, ESTOL C, GORELICK P, GU V, HERMANSSON K, HILBRICH L, KASTE M, LU C, MACHNIG T, PAIS P, ROBERTS R, SKVORTSOVA V, TEAL P, TONI D, VANDERMAELEN C, VOIGT T, WEBER M, YOON BW, COMI , GIANCARLO, Yusuf, S, Diener, Hc, Sacco, Rl, Cotton, D, Ounpuu, S, LAWTON WA PALESCH Y., MARTIN RH ALBERS GW, Bath, P, Bornstein, N, Chan, Bp, Chen, St, Cunha, L, Dahlof, B, DE KEYSER, J, Donnan, Ga, Estol, C, Gorelick, P, Gu, V, Hermansson, K, Hilbrich, L, Kaste, M, Lu, C, Machnig, T, Pais, P, Roberts, R, Skvortsova, V, Teal, P, Toni, D, Vandermaelen, C, Voigt, T, Weber, M, Yoon, Bw, and Comi, Giancarlo
- Published
- 2008
8. Genome comparisons reveal a dominant mechanism of chromosome number reduction in grasses and accelerated genome evolution in Triticeae.
- Author
-
Luo, M. C., Deal, K. R., Akhunov, E. D., Akhunova, A. R., Anderson, O. D., Anderson, J. A., Blake, N., Clegg, M. T., Coleman-Derr, D., Conley, E. J., Crossman, C. C., Dubcovsky, J., Gill, B. S., Gu, V. Q., Hadam, J., Heo, H. Y., Huo, N., Lazo, G., Ma, Y., and Matthews, D. E.
- Subjects
GENETIC polymorphisms ,GENE expression ,AEGILOPS ,SORGHUM genetics ,RICE genetics ,NUCLEOTIDE sequence ,GENOMES - Abstract
Single-nucleotide polymorphism was used in the construction of an expressed sequence tag map of Aegilops tauschii, the diploid source of the wheat D genome. Comparisons of the map with the rice and sorghum genome sequences revealed 50 inversions and translocations; 2,8, and 40 were assigned respectively to the rice, sorghum, and Ae. tauschii lineages, showing greatly accelerated genome evolution in the large Triticeae genomes. The reduction of the basic chromosome number from 12 to 7 in the Triticeae has taken place by a process during which an entire chromosome is inserted by its telomeres into a break in the centromeric region of another chromosome. The original centromere-telomere polarity of the chromosome arms is maintained in the new chromosome. An intrachromosomal telomere-telomere fusion resulting in a pericentric translocation of a chromosome segment or an entire arm accompanied or preceded the chromosome insertion in some instances. Insertional dysploidy has been recorded in three grass subfamilies and appears to be the dominant mechanism of basic chromosome number reduction in grasses. A total of 64% and 66% of Ae. tauschii genes were syntenic with sorghum and rice genes, respectively. Synteny was reduced in the vicinity of the termini of modern Ae. tauschii chromosomes but not in the vicinity of the ancient termini embedded in the Ae. tauschii chromosomes. suggesting that the dependence of synteny erosion on gene location along the centromere-telomere axis either evolved recently in the Triticeae phylogenetic lineage or its evolution was recently accelerated. [ABSTRACT FROM AUTHOR]
- Published
- 2009
- Full Text
- View/download PDF
9. Topics In Lean Supply Chain Management: Second Edition
- Author
-
Schniederjans, M. J., Dara Schniederjans, Cao, R. Q., and Gu, V. C.
10. 57O A phase I/II multicenter, first-in-human study of DB-1311/BNT324 (a novel B7H3 ADC) in patients with advanced solid tumors.
- Author
-
Cheng, Y., Wu, L., Parsonson, A., Amin, H., Shi, J., Lemech, C., Sun, Y., Schmidt, A., Lv, D., Li, M., Zheng, T., Chaudhry, A., Gandhi, C., Wang, Q., Motino, D.A. Montoya, Abed, A., Tibes, R., Lu, X., Gu, V., and Lisberg, A.E.
- Subjects
- *
TUMORS - Published
- 2024
- Full Text
- View/download PDF
11. A systematic literature review on how consumer and community involvement have shaped and influenced pre-pregnancy care interventions for women with diabetes.
- Author
-
Hicks R, Dune T, Gu V, Simmons D, and MacMillan F
- Subjects
- Humans, Female, Pregnancy, Preconception Care methods, Pregnancy in Diabetics therapy, Pregnancy in Diabetics psychology, Diabetes Mellitus therapy, Diabetes Mellitus psychology, Community Participation methods
- Abstract
Background: Diabetes and pregnancy studies have found better outcomes when interventions were developed with consumer (individuals with lived experience of diabetes) and community involvement. When consumers are central to development and delivery of interventions, study participants have better engagement and outcomes, particularly for individuals from culturally and linguistically diverse (CALD) and/or lower socio-economic backgrounds. Our study aims to examine the scope of consumer and community involvement (CCI) in the construction and implementation of pre-pregnancy care (PPC) interventions and discuss a framework for consumer-lead intervention development., Methods: A systematic literature review was conducted, examining 3 electronic databases. A meta synthesis analysis of tabulated data summarized in a literature matrix was undertaken with a phenomenological approach to develop a Pre-Pregnancy Care CCI-Driven Intervention Framework., Results: Overall, 4642 papers were identified, with 29 meeting inclusion criteria. The meta-synthesis and literature matrix identified several common themes across previous studies. These were: barriers to accessing (PPC) such as negativity and stigma in care from behaviours, attitudes and perceptions of HCPs; limited appointment availability not aligning with work and family commitments; fear of losing a "normal" pregnancy journey; awareness of risk but unwillingness to discuss if consumers have not established trust with HCPs; inaccessibility to CALD appropriate PPC and contraception; and digitisation of PPC information resources including peer support and social media. From these results, a PPC Consumer-Driven Intervention Framework for Women with Pregestational Diabetes was developed with recommendations., Conclusion: Consumers have been under-involved in the majority of previous developments and implementation of interventions for women with diabetes and pregnancy, and their representation as stakeholders in interventions is paramount to the longevity of intervention outcomes. To assist community involvement in diabetes pregnancy intervention design and delivery we created a new framework, for improving clinical and social outcomes in healthcare, empowering relationships between HCPs and consumers, and highlighting the value of lived experience and women-centred care for increased community engagement., Competing Interests: Declarations Ethics approval and consent to participate Not applicable. Consent for publication Not applicable. Competing interests The authors declare no competing interests., (© 2024. The Author(s).)
- Published
- 2024
- Full Text
- View/download PDF
12. Art-making to deepen our understanding of illness.
- Author
-
Gu V
- Subjects
- Comprehension, Humans, Art, Disease
- Abstract
Competing Interests: Competing interests: None declared.
- Published
- 2019
- Full Text
- View/download PDF
13. Evidence for the use of complementary and alternative medicines during fertility treatment: a scoping review.
- Author
-
Miner SA, Robins S, Zhu YJ, Keeren K, Gu V, Read SC, and Zelkowitz P
- Subjects
- Acupuncture Therapy, Female, Humans, Male, Reproductive Health, Complementary Therapies, Infertility therapy
- Abstract
Background: Complementary and alternative medicines (CAM) are sometimes used by individuals who desire to improve the outcomes of their fertility treatment and/or mental health during fertility treatment. However, there is little comprehensive information available that analyzes various CAM methods across treatment outcomes and includes information that is published in languages other than English., Method: This scoping review examines the evidence for 12 different CAM methods used to improve female and male fertility outcomes as well as their association with improving mental health outcomes during fertility treatment. Using predefined key words, online medical databases were searched for articles (n = 270). After exclusion criteria were applied, 148 articles were analyzed in terms of their level of evidence and the potential for methodological and author bias., Results: Surveying the literature on a range of techniques, this scoping review finds a lack of high quality evidence that complementary and alternative medicine (CAM) improves fertility or mental health outcomes for men or women. Acupuncture has the highest level of evidence for its use in improving male and female fertility outcomes although this evidence is inconclusive., Conclusion: Overall, the quality of the evidence across CAM methods was poor not only because of the use of research designs that do not yield conclusive results, but also because results were contradictory. There is a need for more research using strong methods such as randomized controlled trials to determine the effectiveness of CAM in relation to fertility treatment, and to help physicians and patients make evidence-based decisions about CAM use during fertility treatment.
- Published
- 2018
- Full Text
- View/download PDF
14. Intrapartum Synthetic Oxytocin and Its Effects on Maternal Well-Being at 2 Months Postpartum.
- Author
-
Gu V, Feeley N, Gold I, Hayton B, Robins S, Mackinnon A, Samuel S, Carter CS, and Zelkowitz P
- Subjects
- Adult, Female, Humans, Labor, Obstetric, Postpartum Period, Pregnancy, Risk Factors, Anxiety epidemiology, Breast Feeding statistics & numerical data, Depression, Postpartum epidemiology, Labor, Induced statistics & numerical data, Mental Health, Oxytocics, Oxytocin blood, Somatoform Disorders epidemiology, Stress Disorders, Post-Traumatic epidemiology
- Abstract
Background: Synthetic oxytocin (synOT) is commonly used in labor management to induce and augment labor, and to prevent postpartum hemorrhage. However, its long-term consequences for maternal health and behavior are largely understudied. We examined the relationship between synOT and maternal oxytocin levels, breastfeeding, and maternal mental health at 2 months postpartum., Methods: Women were recruited during pregnancy or within 48 hours of giving birth through obstetric practices and hospitals. A total of 386 women were visited in their homes at 2 months postpartum, where they completed questionnaires assessing breastfeeding, depression, anxiety, posttraumatic stress, and somatization. Oxytocin levels were obtained from blood samples and synOT dosage information was gathered from hospital charts., Results: Intrapartum synOT dose was positively correlated with endogenous oxytocin levels at 2 months postpartum. Women who were exclusively breastfeeding at 2 months postpartum had received significantly less synOT compared with their nonexclusively breastfeeding counterparts. Higher synOT dose was associated with greater depressive, anxious, and somatization symptoms. SynOT dose was not associated with perinatal posttraumatic stress., Conclusions: The widespread use of synOT in managed labor warrants caution, as the influence of synOT on a new mother's well-being is evident at 2 months postpartum., (© 2015 Wiley Periodicals, Inc.)
- Published
- 2016
- Full Text
- View/download PDF
15. Investigating the effects of antipsychotics and schizotypy on the N400 using event-related potentials and semantic categorization.
- Author
-
Gu V, Mohamed Ali O, L'Abbée Lacas K, and Debruille JB
- Subjects
- Brain drug effects, Brain physiopathology, Brain Mapping methods, Cognition drug effects, Evoked Potentials drug effects, Humans, Magnetic Resonance Imaging methods, Semantics, Antipsychotic Agents pharmacology, Electroencephalography drug effects, Schizotypal Personality Disorder physiopathology
- Abstract
Within the field of cognitive neuroscience, functional magnetic resonance imaging (fMRI) is a popular method of visualizing brain function. This is in part because of its excellent spatial resolution, which allows researchers to identify brain areas associated with specific cognitive processes. However, in the quest to localize brain functions, it is relevant to note that many cognitive, sensory, and motor processes have temporal distinctions that are imperative to capture, an aspect that is left unfulfilled by fMRI's suboptimal temporal resolution. To better understand cognitive processes, it is thus advantageous to utilize event-related potential (ERP) recording as a method of gathering information about the brain. Some of its advantages include its fantastic temporal resolution, which gives researchers the ability to follow the activity of the brain down to the millisecond. It also directly indexes both excitatory and inhibitory post-synaptic potentials by which most brain computations are performed. This sits in contrast to fMRI, which captures an index of metabolic activity. Further, the non-invasive ERP method does not require a contrast condition: raw ERPs can be examined for just one experimental condition, a distinction from fMRI where control conditions must be subtracted from the experimental condition, leading to uncertainty in associating observations with experimental or contrast conditions. While it is limited by its poor spatial and subcortical activity resolution, ERP recordings' utility, relative cost-effectiveness, and associated advantages offer strong rationale for its use in cognitive neuroscience to track rapid temporal changes in neural activity. In an effort to foster increase in its use as a research imaging method, and to ensure proper and accurate data collection, the present article will outline - in the framework of a paradigm using semantic categorization to examine the effects of antipsychotics and schizotypy on the N400 - the procedure and key aspects associated with ERP data acquisition.
- Published
- 2014
- Full Text
- View/download PDF
16. Role of caveolin 1 in AT1a receptor-mediated uptake of angiotensin II in the proximal tubule of the kidney.
- Author
-
Li XC, Gu V, Miguel-Qin E, and Zhuo JL
- Subjects
- Animals, Blood Pressure drug effects, Caveolin 1 genetics, Cells, Cultured, Kidney Tubules, Proximal cytology, Male, Mice, Knockout, Mitogen-Activated Protein Kinase 1 metabolism, Mitogen-Activated Protein Kinase 3 metabolism, RNA, Small Interfering metabolism, Sodium-Hydrogen Exchanger 3, Sodium-Hydrogen Exchangers biosynthesis, Angiotensin II metabolism, Caveolin 1 physiology, Kidney Tubules, Proximal metabolism, Receptor, Angiotensin, Type 1 metabolism
- Abstract
Caveolin 1 (CAV-1) functions not only as a constitutive scaffolding protein of caveolae but also as a vesicular transporter and signaling regulator. In the present study, we tested the hypothesis that CAV-1 knockout (CAV-1 KO) inhibits ANG II type 1 [AT1 (AT1a)] receptor-mediated uptake of ANG II in the proximal tubule and attenuates blood pressure responses in ANG II-induced hypertension. To determine the role of CAV-1 in mediating the uptake of FITC-labeled ANG II, wild-type (WT) mouse proximal convoluted tubule cells were transfected with CAV-1 small interfering (si)RNA for 48 h before AT1 receptor-mediated uptake of FITC-labeled ANG II was studied. CAV-1 siRNA knocked down CAV-1 expression by >90% (P < 0.01) and inhibited FITC-labeled ANG II uptake by >50% (P < 0.01). Moreover, CAV-1 siRNA attenuated ANG II-induced activation of MAPK ERK1/2 and Na(+)/H(+) exchanger 3 expression, respectively (P < 0.01). To determine whether CAV-1 regulates ANG II uptake in the proximal tubule, Alexa 488-labeled ANG II was infused into anesthetized WT and CAV-1 KO mice for 60 min (20 ng/min iv). Imaging analysis revealed that Alexa 488-labeled ANG II uptake was decreased by >50% in CAV-1 KO mice (P < 0.01). Furthermore, Val(5)-ANG II was infused into WT and CAV-1 KO mice for 2 wk (1.5 mg·kg(-1)·day(-1) ip). Basal systolic pressure was higher, whereas blood pressure and renal excretory and signaling responses to ANG II were attenuated, in CAV-1 KO mice (P < 0.01). We concluded that CAV-1 plays an important role in AT1 receptor-mediated uptake of ANG II in the proximal tubule and modulates blood pressure and renal responses to ANG II., (Copyright © 2014 the American Physiological Society.)
- Published
- 2014
- Full Text
- View/download PDF
17. Performing label-fusion-based segmentation using multiple automatically generated templates.
- Author
-
Chakravarty MM, Steadman P, van Eede MC, Calcott RD, Gu V, Shaw P, Raznahan A, Collins DL, and Lerch JP
- Subjects
- Adolescent, Algorithms, Animals, Child, Child, Preschool, Contrast Media, Female, Gadolinium, Humans, Male, Mice, Nonlinear Dynamics, Normal Distribution, Observer Variation, Organ Size, Reference Values, Reproducibility of Results, Atlases as Topic, Brain anatomy & histology, Magnetic Resonance Imaging, Mice, Inbred C57BL anatomy & histology, Pattern Recognition, Automated
- Abstract
Classically, model-based segmentation procedures match magnetic resonance imaging (MRI) volumes to an expertly labeled atlas using nonlinear registration. The accuracy of these techniques are limited due to atlas biases, misregistration, and resampling error. Multi-atlas-based approaches are used as a remedy and involve matching each subject to a number of manually labeled templates. This approach yields numerous independent segmentations that are fused using a voxel-by-voxel label-voting procedure. In this article, we demonstrate how the multi-atlas approach can be extended to work with input atlases that are unique and extremely time consuming to construct by generating a library of multiple automatically generated templates of different brains (MAGeT Brain). We demonstrate the efficacy of our method for the mouse and human using two different nonlinear registration algorithms (ANIMAL and ANTs). The input atlases consist a high-resolution mouse brain atlas and an atlas of the human basal ganglia and thalamus derived from serial histological data. MAGeT Brain segmentation improves the identification of the mouse anterior commissure (mean Dice Kappa values (κ = 0.801), but may be encountering a ceiling effect for hippocampal segmentations. Applying MAGeT Brain to human subcortical structures improves segmentation accuracy for all structures compared to regular model-based techniques (κ = 0.845, 0.752, and 0.861 for the striatum, globus pallidus, and thalamus, respectively). Experiments performed with three manually derived input templates suggest that MAGeT Brain can approach or exceed the accuracy of multi-atlas label-fusion segmentation (κ = 0.894, 0.815, and 0.895 for the striatum, globus pallidus, and thalamus, respectively)., (Copyright © 2012 Wiley Periodicals, Inc.)
- Published
- 2013
- Full Text
- View/download PDF
18. Evidence for a functional intracellular angiotensin system in the proximal tubule of the kidney.
- Author
-
Ellis B, Li XC, Miguel-Qin E, Gu V, and Zhuo JL
- Subjects
- Animals, Blood Pressure physiology, Cell Nucleus physiology, Cytoplasm physiology, Mice, Models, Animal, Rats, Receptor, Angiotensin, Type 1 physiology, Angiotensin II physiology, Kidney Tubules, Proximal cytology, Kidney Tubules, Proximal physiology, Renin-Angiotensin System physiology
- Abstract
ANG II is the most potent and important member of the classical renin-angiotensin system (RAS). ANG II, once considered to be an endocrine hormone, is now increasingly recognized to also play novel and important paracrine (cell-to-cell) and intracrine (intracellular) roles in cardiovascular and renal physiology and blood pressure regulation. Although an intracrine role of ANG II remains an issue of continuous debates and requires further confirmation, a great deal of research has recently been devoted to uncover the novel actions and elucidate underlying signaling mechanisms of the so-called intracellular ANG II in cardiovascular, neural, and renal systems. The purpose of this article is to provide a comprehensive review of the intracellular actions of ANG II, either administered directly into the cells or expressed as an intracellularly functional fusion protein, and its effects throughout a variety of target tissues susceptible to the impacts of an overactive ANG II, with a particular focus on the proximal tubules of the kidney. While continuously reaffirming the roles of extracellular or circulating ANG II in the proximal tubules, our review will focus on recent evidence obtained for the novel biological roles of intracellular ANG II in cultured proximal tubule cells in vitro and the potential physiological roles of intracellular ANG II in the regulation of proximal tubular reabsorption and blood pressure in rats and mice. It is our hope that the new knowledge on the roles of intracellular ANG II in proximal tubules will serve as a catalyst to stimulate further studies and debates in the field and to help us better understand how extracellular and intracellular ANG II acts independently or interacts with each other, to regulate proximal tubular transport and blood pressure in both physiological and diseased states.
- Published
- 2012
- Full Text
- View/download PDF
19. Effects of aspirin plus extended-release dipyridamole versus clopidogrel and telmisartan on disability and cognitive function after recurrent stroke in patients with ischaemic stroke in the Prevention Regimen for Effectively Avoiding Second Strokes (PRoFESS) trial: a double-blind, active and placebo-controlled study.
- Author
-
Diener HC, Sacco RL, Yusuf S, Cotton D, Ounpuu S, Lawton WA, Palesch Y, Martin RH, Albers GW, Bath P, Bornstein N, Chan BP, Chen ST, Cunha L, Dahlöf B, De Keyser J, Donnan GA, Estol C, Gorelick P, Gu V, Hermansson K, Hilbrich L, Kaste M, Lu C, Machnig T, Pais P, Roberts R, Skvortsova V, Teal P, Toni D, VanderMaelen C, Voigt T, Weber M, and Yoon BW
- Subjects
- Aged, Aspirin therapeutic use, Clopidogrel, Dipyridamole therapeutic use, Disability Evaluation, Double-Blind Method, Drug Administration Schedule, Drug Delivery Systems, Drug Therapy, Combination, Female, Follow-Up Studies, Humans, International Cooperation, Male, Mental Status Schedule, Middle Aged, Retrospective Studies, Secondary Prevention, Severity of Illness Index, Telmisartan, Ticlopidine analogs & derivatives, Ticlopidine therapeutic use, Angiotensin II Type 1 Receptor Blockers therapeutic use, Benzimidazoles therapeutic use, Benzoates therapeutic use, Cognition drug effects, Platelet Aggregation Inhibitors therapeutic use, Stroke physiopathology, Stroke prevention & control
- Abstract
Background: The treatment of ischaemic stroke with neuroprotective drugs has been unsuccessful, and whether these compounds can be used to reduce disability after recurrent stroke is unknown. The putative neuroprotective effects of antiplatelet compounds and the angiotensin II receptor antagonist telmisartan were investigated in the Prevention Regimen for Effectively Avoiding Second Strokes (PRoFESS) trial., Methods: Patients who had had an ischaemic stroke were randomly assigned in a two by two factorial design to receive either 25 mg aspirin (ASA) and 200 mg extended-release dipyridamole (ER-DP) twice a day or 75 mg clopidogrel once a day, and either 80 mg telmisartan or placebo once per day. The predefined endpoints for this substudy were disability after a recurrent stroke, assessed with the modified Rankin scale (mRS) and Barthel index at 3 months, and cognitive function, assessed with the mini-mental state examination (MMSE) score at 4 weeks after randomisation and at the penultimate visit. Analysis was by intention to treat. The study was registered with ClinicalTrials.gov, number NCT00153062., Findings: 20,332 patients (mean age 66 years) were randomised and followed-up for a median of 2.4 years. Recurrent strokes occurred in 916 (9%) patients randomly assigned to ASA with ER-DP and 898 (9%) patients randomly assigned to clopidogrel; 880 (9%) patients randomly assigned to telmisartan and 934 (9%) patients given placebo had recurrent strokes. mRS scores were not statistically different in patients with recurrent stroke who were treated with ASA and ER-DP versus clopidogrel (p=0.38), or with telmisartan versus placebo (p=0.61). There was no significant difference in the proportion of patients with recurrent stroke with a good outcome, as measured with the Barthel index, across all treatment groups. Additionally, there was no significant difference in the median MMSE scores, the percentage of patients with an MMSE score of 24 points or less, the percentage of patients with a drop in MMSE score of 3 points or more between 1 month and the penultimate visit, and the number of patients with dementia among the treatment groups. There were no significant differences in the proportion of patients with cognitive impairment or dementia among the treatment groups., Interpretation: Disability due to recurrent stroke and cognitive decline in patients with ischaemic stroke were not different between the two antiplatelet regimens and were not affected by the preventive use of telmisartan.
- Published
- 2008
- Full Text
- View/download PDF
20. Telmisartan to prevent recurrent stroke and cardiovascular events.
- Author
-
Yusuf S, Diener HC, Sacco RL, Cotton D, Ounpuu S, Lawton WA, Palesch Y, Martin RH, Albers GW, Bath P, Bornstein N, Chan BP, Chen ST, Cunha L, Dahlöf B, De Keyser J, Donnan GA, Estol C, Gorelick P, Gu V, Hermansson K, Hilbrich L, Kaste M, Lu C, Machnig T, Pais P, Roberts R, Skvortsova V, Teal P, Toni D, VanderMaelen C, Voigt T, Weber M, and Yoon BW
- Subjects
- Aged, Angiotensin-Converting Enzyme Inhibitors adverse effects, Benzimidazoles adverse effects, Benzoates adverse effects, Blood Pressure drug effects, Cardiovascular Diseases epidemiology, Cardiovascular Diseases mortality, Creatinine blood, Diabetes Mellitus epidemiology, Female, Follow-Up Studies, Heart Failure epidemiology, Heart Failure prevention & control, Humans, Kaplan-Meier Estimate, Male, Middle Aged, Myocardial Infarction epidemiology, Myocardial Infarction prevention & control, Potassium blood, Secondary Prevention, Stroke prevention & control, Telmisartan, Treatment Failure, Angiotensin-Converting Enzyme Inhibitors therapeutic use, Benzimidazoles therapeutic use, Benzoates therapeutic use, Cardiovascular Diseases prevention & control, Stroke drug therapy
- Abstract
Background: Prolonged lowering of blood pressure after a stroke reduces the risk of recurrent stroke. In addition, inhibition of the renin-angiotensin system in high-risk patients reduces the rate of subsequent cardiovascular events, including stroke. However, the effect of lowering of blood pressure with a renin-angiotensin system inhibitor soon after a stroke has not been clearly established. We evaluated the effects of therapy with an angiotensin-receptor blocker, telmisartan, initiated early after a stroke., Methods: In a multicenter trial involving 20,332 patients who recently had an ischemic stroke, we randomly assigned 10,146 to receive telmisartan (80 mg daily) and 10,186 to receive placebo. The primary outcome was recurrent stroke. Secondary outcomes were major cardiovascular events (death from cardiovascular causes, recurrent stroke, myocardial infarction, or new or worsening heart failure) and new-onset diabetes., Results: The median interval from stroke to randomization was 15 days. During a mean follow-up of 2.5 years, the mean blood pressure was 3.8/2.0 mm Hg lower in the telmisartan group than in the placebo group. A total of 880 patients (8.7%) in the telmisartan group and 934 patients (9.2%) in the placebo group had a subsequent stroke (hazard ratio in the telmisartan group, 0.95; 95% confidence interval [CI], 0.86 to 1.04; P=0.23). Major cardiovascular events occurred in 1367 patients (13.5%) in the telmisartan group and 1463 patients (14.4%) in the placebo group (hazard ratio, 0.94; 95% CI, 0.87 to 1.01; P=0.11). New-onset diabetes occurred in 1.7% of the telmisartan group and 2.1% of the placebo group (hazard ratio, 0.82; 95% CI, 0.65 to 1.04; P=0.10)., Conclusions: Therapy with telmisartan initiated soon after an ischemic stroke and continued for 2.5 years did not significantly lower the rate of recurrent stroke, major cardiovascular events, or diabetes. (ClinicalTrials.gov number, NCT00153062.), (2008 Massachusetts Medical Society)
- Published
- 2008
- Full Text
- View/download PDF
21. Calreticulin in human pregnancy and pre-eclampsia.
- Author
-
Gu VY, Wong MH, Stevenson JL, Crawford KE, Brennecke SP, and Gude NM
- Subjects
- Calreticulin genetics, Case-Control Studies, Cells, Cultured, Female, Gene Expression Regulation, Humans, Placenta metabolism, Pre-Eclampsia genetics, RNA, Messenger metabolism, Calreticulin blood, Calreticulin metabolism, Pre-Eclampsia blood, Pre-Eclampsia metabolism, Pregnancy blood, Pregnancy metabolism
- Abstract
Pre-eclampsia is a disorder of human pregnancy that involves pregnancy-induced maternal hypertension and proteinuria. Evidence indicates that pre-eclampsia involves widespread activation of maternal endothelial cells. Calreticulin is a ubiquitously expressed, multi-functional protein that has been shown to have both pro- and anti-inflammatory effects on cultured endothelial cells in vitro and in whole animals. In order to clarify the role of this protein in normal human pregnancy and in pre-eclampsia, this study has measured expression of calreticulin in maternal blood and in placenta in patients with pre-eclampsia and in control pregnancies. There was a significant increase (approximately 5-fold) in calreticulin in plasma in term pregnant women compared with women who were not pregnant. There was no difference, however, in calreticulin in plasma from women who were sampled at first trimester, second trimester and at term. In addition, there was a significant increase (approximately 50%) in calreticulin in plasma from pre-eclamptic women compared to controls. Calreticulin mRNA and protein expression in placenta were not changed between pre-eclampsia and control pregnancies. These novel results indicate that calreticulin is increased in peripheral maternal blood early in pregnancy and remains elevated throughout normal gestation and that there is a further increase in calreticulin in pre-eclampsia.
- Published
- 2008
- Full Text
- View/download PDF
22. Anopheles gambiae s.l. and Anopheles funestus mosquito distributions at 30 villages along the Kenyan coast.
- Author
-
Keating J, Mbogo CM, Mwangangi J, Nzovu JG, Gu V, Regens JL, Yan G, Githure JI, and Beier JC
- Subjects
- Animals, Kenya, Mosquito Control, Population Density, Seasons, Anopheles growth & development
- Abstract
This study investigated whether Anopheles gambiae s.l. and Anopheles funestus Giles mosquito populations were distributed randomly among houses on the coast of Kenya. Sample means and variances of mosquitoes were estimated from bimonthly pyrethrum spray collections at 30 villages from July 1997 through May 1998. In total, 5,476 An. gambiae s.l. and 3,461 An. funestus were collected. The number of An. gambiae s.l. collected was highest in November/December and lowest in May. The number of An. funestus collected was highest during September/October and lowest during May. As the density of mosquitoes decreased, there was a tendency toward randomness in the distribution. The proportion of An. gambiae s.l. and An. funestus mosquitoes collected per house for each sampling period also showed patterns of clustering, with 80% of An. gambiae s.l. collected from <30% of the houses and 80% of An. funestus collected from <20% of the total houses. The total number of mosquitoes collected from any one house ranged from 0 to 121 for An. gambiae s.l. and from 0 to 152 for An. funestus. This coupled with the results of the variance to mean ratio plots suggests extensive clustering in the distribution of An. gambiae s.l. and An. funestus mosquito populations throughout the year along the coast of Kenya.
- Published
- 2005
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.